View ValuationGubra 향후 성장Future 기준 점검 5/6Gubra (는) 각각 연간 7.9% 및 9.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 12.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 23.5% 로 예상됩니다.핵심 정보7.9%이익 성장률12.13%EPS 성장률Life Sciences 이익 성장17.5%매출 성장률9.9%향후 자기자본이익률23.50%애널리스트 커버리지Low마지막 업데이트25 Jul 2025최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 04Gubra A/S, Annual General Meeting, Mar 26, 2026Gubra A/S, Annual General Meeting, Mar 26, 2026, at 10:00 Romance Standard Time. Location: horsholm kongevej 11b, 2970, Denmark공시 • Feb 19+ 1 more updateGubra A/S to Report First Half, 2026 Results on Aug 20, 2026Gubra A/S announced that they will report first half, 2026 results on Aug 20, 2026공시 • Jan 08Amylyx Pharmaceuticals, Inc. Announces Nomination of Amx0318 as A Novel, Long-Acting Glp-1 Receptor AntagonistAmylyx Pharmaceuticals, Inc. announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 was identified through a research collaboration with Gubra A/S. AMX0318 has completed extensive preclinical evaluation, including stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and in vivo tolerability studies. Amylyx expects the program to advance into investigational new drug (IND)-enabling studies later this year, with an IND targeted for 2027, pending successful completion of IND-enabling studies. Under the terms of the research collaboration, Gubra is eligible to receive more than $50 million in success-based development and commercialization milestones plus mid-single digit royalties on worldwide net sales. The selection and handover of the development candidate will provide milestone payments of $4 million to Gubra.공시 • Jan 05Gubra Announces Executive ChangesGubra announced the appointment of Thomas Langenickel, M.D., as Chief Medical and Development Officer (CMDO) effective January 5, 2026. Dr. Langenickel brings more than two decades of experience in big pharma and biotech, spanning drug discovery, translational medicine, and clinical development. In his new role, he will join Gubra’s Leadership Team and guide the company’s preclinical and clinical development strategy as its pipeline advances toward key milestones. Dr. Langenickel most recently served as Chief Medical Officer at Ethris, where he led the development of early clinical assets in respiratory and infectious diseases. His prior experience includes senior roles at Novartis as Executive Director of Translational Medicine and Profiling, and at Bristol Myers Squibb as Medical Director. He earned his M.D. from Humboldt University of Berlin and completed a postdoctoral fellowship in vascular biology at the National Heart, Lung, and Blood Institute, NIH (USA). Gubra also extends its gratitude to Dr. Mads Axelsen, who retired in December after serving as CMO. His leadership and contributions have been instrumental in shaping Gubra's development organization and supporting the company's growth.공시 • Jun 27Gubra A/S Approves Distribution of Extraordinary Cash DividendsGubra A/S at its EGM held on June 27, 2025, approved a distribution of extraordinary cash dividends to the Company's shareholders in the amount of DKK 1 billion, corresponding to DKK 61.2 per share of a nominal value of DKK 1.공시 • Jun 03Gubra A/S Proposes Extraordinary Cash DividendGubra A/S board of directors proposed that the extraordinary general meeting to be held on 27 June 2025, approves a distribution of extraordinary cash dividends to the Company's shareholders in the amount of DKK 1,000 million, corresponding to DKK 61.2 (rounded) per share of a nominal value of DKK 1.공시 • Apr 04Gubra A/S Approves Board ChangesGubra A/S in its annual general meeting held on 3 April, 2025, Henriette Dræbye Rosenquist did not stand for re-election. The Board extends heartfelt Henriette for her significant contributions wishing her all the best in her new endeavours. The Board welcomes Gubra Co-Founder and Scientific Advisor Niels Vrang's re-entry to the board and Claudia Mitchell as new members of the Board. Their collective experience in biotech innovation, research, and entrepreneurship will be a valuable asset to the next chapters in the company's growth journey. Monika Lessl, previously serving as a Board member, has been appointed as the new Chair, succeeding Jacob Jelsing, who remains an active member of the Board. As internationally experienced pharma and life science executive with more than 25 years of R&D and Innovation leadership, Monika brings visionary leadership and deep insight into innovation and sustainability - two key pillars of Gubra's mission.공시 • Mar 11Gubra A/S, Annual General Meeting, Apr 03, 2025Gubra A/S, Annual General Meeting, Apr 03, 2025, at 10:00 Romance Standard Time. Location: horsholm kongevej 11b, dk-2970, horsholm, Denmark공시 • Mar 10Gubra A/S Announces Board ChangesGubra A/S announced Henriette Dræbye Rosenquist does not stand for re-election. The board of directors notes that Jacob Jelsing will step down as chair of the board of directors in connection with the annual general meeting but will continue to serve as an ordinary member of the board of directors.공시 • Feb 27+ 1 more updateGubra A/S to Report First Half, 2025 Results on Aug 21, 2025Gubra A/S announced that they will report first half, 2025 results on Aug 21, 2025공시 • Jan 15Gubra Appoints Anne-Marie Levy Rasmussen as Chief Operating OfficerGubra announced the appointment of Anne-Marie Levy Rasmussen as the company's new Chief Operating Officer (COO). Anne-Marie brings a strong international experience and track record from global pharma companies such as GlaxoSmithKline and Bavarian Nordic within operational leadership, scaling and establishment of solid governance routines in complex settings. Most recently as Head of Global Commercial Operations at Bavarian Nordic. As COO in Gubra, Anne-Marie will be member of the Executive Management Team and be responsible for overseeing the company's operational strategy, optimizing processes, and driving efficiency across departments and key projects. Her extensive background within leadership, scaling and system integration with new digital approaches positions her well to contribute to Gubra's continued growth and innovation. Anne-Marie's theoretical background is a MSc Physics from University of Copenhagen.이익 및 매출 성장 예측OTCPK:GUBR.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (DKK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2027881749859772212/31/2026454168279191212/31/20252,8301,9492,0591,971212/31/2024266-36-275N/A9/30/2024245-42-39-10N/A6/30/2024224-47-50-25N/A3/31/2024214-46-55-37N/A12/31/2023205-45-61-49N/A9/30/2023204-26-58-47N/A6/30/2023204-7-56-45N/A3/31/2023201-1-23-10N/A12/31/202219941024N/A12/31/2021255686189N/A12/31/2020172132633N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: GUBR.F 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(2.9%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: GUBR.F (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: GUBR.F 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: GUBR.F 의 수익(연간 9.9%)이 US 시장(연간 11.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: GUBR.F 의 수익(연간 9.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: GUBR.F의 자본 수익률은 3년 후 23.5%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/08/03 06:47종가2025/05/06 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Gubra A/S는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Rune DahlDNB CarnegieJesper IlsøeDNB CarnegieRajan SharmaGoldman Sachs
공시 • Mar 04Gubra A/S, Annual General Meeting, Mar 26, 2026Gubra A/S, Annual General Meeting, Mar 26, 2026, at 10:00 Romance Standard Time. Location: horsholm kongevej 11b, 2970, Denmark
공시 • Feb 19+ 1 more updateGubra A/S to Report First Half, 2026 Results on Aug 20, 2026Gubra A/S announced that they will report first half, 2026 results on Aug 20, 2026
공시 • Jan 08Amylyx Pharmaceuticals, Inc. Announces Nomination of Amx0318 as A Novel, Long-Acting Glp-1 Receptor AntagonistAmylyx Pharmaceuticals, Inc. announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 was identified through a research collaboration with Gubra A/S. AMX0318 has completed extensive preclinical evaluation, including stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and in vivo tolerability studies. Amylyx expects the program to advance into investigational new drug (IND)-enabling studies later this year, with an IND targeted for 2027, pending successful completion of IND-enabling studies. Under the terms of the research collaboration, Gubra is eligible to receive more than $50 million in success-based development and commercialization milestones plus mid-single digit royalties on worldwide net sales. The selection and handover of the development candidate will provide milestone payments of $4 million to Gubra.
공시 • Jan 05Gubra Announces Executive ChangesGubra announced the appointment of Thomas Langenickel, M.D., as Chief Medical and Development Officer (CMDO) effective January 5, 2026. Dr. Langenickel brings more than two decades of experience in big pharma and biotech, spanning drug discovery, translational medicine, and clinical development. In his new role, he will join Gubra’s Leadership Team and guide the company’s preclinical and clinical development strategy as its pipeline advances toward key milestones. Dr. Langenickel most recently served as Chief Medical Officer at Ethris, where he led the development of early clinical assets in respiratory and infectious diseases. His prior experience includes senior roles at Novartis as Executive Director of Translational Medicine and Profiling, and at Bristol Myers Squibb as Medical Director. He earned his M.D. from Humboldt University of Berlin and completed a postdoctoral fellowship in vascular biology at the National Heart, Lung, and Blood Institute, NIH (USA). Gubra also extends its gratitude to Dr. Mads Axelsen, who retired in December after serving as CMO. His leadership and contributions have been instrumental in shaping Gubra's development organization and supporting the company's growth.
공시 • Jun 27Gubra A/S Approves Distribution of Extraordinary Cash DividendsGubra A/S at its EGM held on June 27, 2025, approved a distribution of extraordinary cash dividends to the Company's shareholders in the amount of DKK 1 billion, corresponding to DKK 61.2 per share of a nominal value of DKK 1.
공시 • Jun 03Gubra A/S Proposes Extraordinary Cash DividendGubra A/S board of directors proposed that the extraordinary general meeting to be held on 27 June 2025, approves a distribution of extraordinary cash dividends to the Company's shareholders in the amount of DKK 1,000 million, corresponding to DKK 61.2 (rounded) per share of a nominal value of DKK 1.
공시 • Apr 04Gubra A/S Approves Board ChangesGubra A/S in its annual general meeting held on 3 April, 2025, Henriette Dræbye Rosenquist did not stand for re-election. The Board extends heartfelt Henriette for her significant contributions wishing her all the best in her new endeavours. The Board welcomes Gubra Co-Founder and Scientific Advisor Niels Vrang's re-entry to the board and Claudia Mitchell as new members of the Board. Their collective experience in biotech innovation, research, and entrepreneurship will be a valuable asset to the next chapters in the company's growth journey. Monika Lessl, previously serving as a Board member, has been appointed as the new Chair, succeeding Jacob Jelsing, who remains an active member of the Board. As internationally experienced pharma and life science executive with more than 25 years of R&D and Innovation leadership, Monika brings visionary leadership and deep insight into innovation and sustainability - two key pillars of Gubra's mission.
공시 • Mar 11Gubra A/S, Annual General Meeting, Apr 03, 2025Gubra A/S, Annual General Meeting, Apr 03, 2025, at 10:00 Romance Standard Time. Location: horsholm kongevej 11b, dk-2970, horsholm, Denmark
공시 • Mar 10Gubra A/S Announces Board ChangesGubra A/S announced Henriette Dræbye Rosenquist does not stand for re-election. The board of directors notes that Jacob Jelsing will step down as chair of the board of directors in connection with the annual general meeting but will continue to serve as an ordinary member of the board of directors.
공시 • Feb 27+ 1 more updateGubra A/S to Report First Half, 2025 Results on Aug 21, 2025Gubra A/S announced that they will report first half, 2025 results on Aug 21, 2025
공시 • Jan 15Gubra Appoints Anne-Marie Levy Rasmussen as Chief Operating OfficerGubra announced the appointment of Anne-Marie Levy Rasmussen as the company's new Chief Operating Officer (COO). Anne-Marie brings a strong international experience and track record from global pharma companies such as GlaxoSmithKline and Bavarian Nordic within operational leadership, scaling and establishment of solid governance routines in complex settings. Most recently as Head of Global Commercial Operations at Bavarian Nordic. As COO in Gubra, Anne-Marie will be member of the Executive Management Team and be responsible for overseeing the company's operational strategy, optimizing processes, and driving efficiency across departments and key projects. Her extensive background within leadership, scaling and system integration with new digital approaches positions her well to contribute to Gubra's continued growth and innovation. Anne-Marie's theoretical background is a MSc Physics from University of Copenhagen.